Dimensional Fund Advisors LP reduced its stake in IRIDEX Corporation (NASDAQ:IRIX) by 16.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 205,145 shares of the medical equipment provider’s stock after selling 40,688 shares during the period. Dimensional Fund Advisors LP owned 1.78% of IRIDEX Corporation worth $2,435,000 at the end of the most recent quarter.
Several equities analysts recently commented on the stock. ValuEngine upgraded shares of IRIDEX Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded shares of IRIDEX Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/17/iridex-corporation-irix-position-lowered-by-dimensional-fund-advisors-lp.html.
Shares of IRIDEX Corporation (IRIX) opened at 9.70 on Friday. The firm’s market capitalization is $112.20 million. The firm’s 50-day moving average is $8.75 and its 200-day moving average is $10.19. IRIDEX Corporation has a 52 week low of $7.58 and a 52 week high of $16.39.
IRIDEX Corporation (NASDAQ:IRIX) last posted its earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.06). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.48 million. IRIDEX Corporation had a negative net margin of 37.62% and a negative return on equity of 16.87%. Equities analysts anticipate that IRIDEX Corporation will post ($0.72) EPS for the current year.
About IRIDEX Corporation
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related companies with MarketBeat.com's FREE daily email newsletter.